7-Oxo-4-thia-1-aza[3,2,0]heptane and 7-oxo-4-thia-1-aza[3,2,0]hept-2-ene derivatives

ABSTRACT

What are disclosed are compounds, useful as intermediates in the preparation of substituted penem compounds, of the formula ##STR1## methods for making such compounds from intermediates of the formula ##STR2## by reaction of the latter with a nucleophilic compound, methods for making such intermediates from compounds of the formula ##STR3## by reaction of the last-mentioned compounds with a tervalent phosphorus compound, and methods for making said last-mentioned compounds by cyclizing compounds of the formula ##STR4## with a tervalent phosphorus compound.

This invention relates to substituted7-oxo-4-thia-1-azabicyclo[3,2,0]heptane and7-oxo-4-thia-1-azabicyclo[3,2,0]hept-2-ene derivatives.

7-oxo-4-thia-1-azabicyclo[3,2,0]heptane has the following structure:##STR5##

The present invention provides a compound of the general formula Ia andits tautomer Ib ##STR6## in which formulae R represents a carboxylesterifying group, and R² represents hydrogen or an aliphatic group.More preferably

R² represents hydrogen, lower alkyl, lower hydroxyalkyl, loweralkoxyalkyl, lower acyloxyalkyl or trilower alkylsiloxyalkyl,

and salts thereof.

The terms "a compound of the general formula I" and "a compound offormula I" are both used hereinafter to denote a compound of the generalformula Ia, a compound of the general formula Ib, or any mixturethereof.

R² may be cis or trans to the carbon-sulfur moiety at position 5. Thestereochemistry at position 5 can be R or S i.e. a compound of formula Imay be 5R, 6R, 5R, 6S; 5S, 6R or 5S, 6S. It is preferable, however, tohave the 5R stereochemistry, (as defined by the Cahn-Ingold-Prelogsystem of nomenclature). A chiral carbon atom is also present atposition 2 in formula Ia, giving further R and S isomers.

The present invention also provides a process for the production of acompound of the general formula I, which comprises treating a compoundof the general formula II ##STR7## in which R and R² are as definedabove, and R¹ represents a lower alkyl group or a phenyl group andrepresents especially a methyl group, with a nucleophilic compound and,if desired, carrying out any one or more of the following steps in anydesired order:

(a) converting a free acid of formula I into an ester thereof,

(b) transesterifying a compound of formula I,

(c) converting a free acid or an ester of formula I into a salt, or asalt into the free acid, an ester, or another salt,

(d) removing any protective groups present other than an esterifyinggroup R.

The treatment of the compound of formula II with a nucleophilic compoundis generally carried out in a solvent, and in some cases the solventitself may also function as the nucleophilic compound.

There can be used either an organic nucleophilic compound or aninorganic nucleophilic compound. Examples of inorganic nucleophiliccompounds are water, alkali metal and alkaline earth metal hydroxides,carbonates and bicarbonates, for example, sodium hydroxide, sodiumcarbonate, sodium bicarbonate, potassium carbonate, potassiumbicarbonate, and magnesium carbonate; borates and phosphates.

Organic nucleophilic compounds are, for example, amines, for example,primary and secondary aliphatic amines, for example, ethylamine,methylamine, diethylamine, and dimethylamine; cycloaliphatic amines, forexample, cyclohexylamine; non-aromatic heterocyclic amines, for example,morpholine, piperidine and piperazine; aromatic heterocyclic amines, forexample, pyridine and substituted pyridines, for example,4-N,N-dimethylaminopyridine, imidazole and substituted, especially loweralkyl substituted, imidazoles, for example, methylimidazole; aromaticamines, for example, aniline and substituted anilines, for example,methyl-substituted anilines, for example, toluidine; and hydrazine andhydroxylamine. Preferred are heterocyclic nitrogen bases having a pKbetween 5 and 9, particularly aromatic nitrogen bases. Most preferred isimidazole.

As mentioned above, the treatment of a compound of formula II with anucleophilic compound is generally carried out in a solvent. In somecases the solvent itself may function also as the nucleophilic compound,as is the case with water.

The solvent is, for example, a water-miscible ether, for example dioxanor tetrahydrofuran; an alcohol, for example, having up to 4 carbonatoms, for example, methanol, ethanol or propanol; water; an amide forexample dimethylformamide, dimethylacetamide, orhexamethylphosphoramide; or dimethylsulphoxide, acetonitrile orsulpholane.

A mixture of any two or more solvents may be used, for example, amixture of water and another solvent, for example, an amide, an alcohol,or an ether.

When the nucleophilic compound is, for example, an alkali metal borateor phosphate salt, this is preferably used in the form of a solutionthereof in water or in a mixture of water and another solvent, thesolution having a pH within the range of from 8 to 11. If thenucleophilic compound is an amine having a pK greater than 7, it ispreferable to buffer the reaction mixture so the pH is within the rangeof from 6 to 8, for example, using Sorenson's phosphate buffer or Clarkand Lubs's borate buffer.

Preferred nucleophilic compounds are alkali metal hydroxides, carbonatesand bicarbonates, especially sodium carbonate, and aromatic heterocyclicamines, especially imidazole. A preferred solvent is a water/dioxanmixture, preferably comprising from 1 to 50% by volume of water indioxan, especially from 5 to 25% water in dioxan.

The reaction is generally carried out at a temperature within the rangefrom the freezing point of the solvent or solvent mixture or -10° C.(whichever is the higher), to 50° C., preferably from 0° to 25° C.

The reaction mixture comprising the resulting compound of formula I ispreferably diluted with water or an aqueous acid, for example aqueouscitric acid, so the resulting mixture has a pH of from 1 to 4, andextracted into an organic solvent, for example, an ester, for example,ethyl acetate or a halogenated hydrocarbon, for example, chloroform. Theresulting compound of formula I is then generally pure enough forfurther use, but if desired, it may be purified further, for example bycrystallisation or chromatography.

In the compounds of formulae I and II, R² preferably represents ahydrogen atom, or an unsubstituted or substituted, straight or branchedchain aliphatic group. An aliphatic group may be a straight or branchedchain lower alkyl, alkenyl or alkynyl group, for example, a methyl,ethyl or vinyl group.

The term "lower" as used herein in all instances denotes a molecule,group or radical having up to 8 carbon atoms, and especially up to 4carbon atoms.

Unless stated otherwise, halogen atoms are fluorine, chlorine, bromineand iodine atoms.

A heterocyclic group preferably has up to 4 heteroatoms, which may bethe same or different, selected from nitrogen, oxygen and sulphur atoms,and up to 14 atoms in total.

The term "known" means in actual use in the art or described in theliterature of the art.

An aliphatic group R² may be substituted, if desired, by one or moresubstituents, which may be the same or different. Examples ofsubstituents are halogen atoms; hydroxyl groups; alkoxy and alkylthiogroups; alkylcarbonyl groups; carboxy, alkoxycarbonyl andalkylthiocarbonyl groups; alkanoyloxy and alkanoylthio groups; nitro,cyano and azido groups; amido and imido groups; amidino and guanidinogroups; imino, amino, mono- and dialkylamino, mono- and diarylaminogroups, and N,N-alkylarylamino groups; acylamino groups; carbamoyl andcarbamoyloxy groups, and carbamoyl and carbamoyloxy groups substitutedon the nitrogen atom by one or two groups selected from alkyl and arylgroups, and the corresponding unsubstituted and substituted groups inwhich the oxygen atom or each or either oxygen atom is replaced by asulphur atom.

Any substituent of R² that is itself capable of substitution may besubstituted, for example, by any one or more of the substituentsdescribed above.

Preferred substituents for an aliphatic group R² are hydroxyl groups,which may themselves be substituted for example, by one of the followinggroups: --R³, --CO--NR³ R⁴, --CO--R³, --CO--OR³, --SO₂ --R³, --SO₂ NH₂,and OSO₃ H, SiR₃ R₄ R₅, in which groups R³, R⁴ and R⁵, which may be thesame or different, if more than one are present, each represents analkyl group, especially a lower alkyl group, an aryl group or an aralkylgroup, especially an aryl-lower alkyl group. Furthermore, the nitrogenatom present in the group --CO--NR³ R⁴ may be part of an aromatic ornon-aromatic heterocyclic ring.

R² especially represents a hydrogen atom, a lower alkyl group, or ahydroxyl-lower alkyl group, for example, a methyl, ethyl, hydroxymethyl,1-hydroxyethyl (R or S) or 2-hydroxyprop-2-yl group, or a vinyl group.

An esterified carboxyl group --COOR is, for example, an ester formedwith an unsubstituted or substituted aliphatic, cycloaliphatic,cycloaliphatic-aliphatic, aryl, araliphatic, heterocyclic orheterocyclic-aliphatic alcohol having up to 20 carbon atoms, or is, forexample, a silyl or stannyl ester.

R may represent, for example a straight or branched chain substituted orunsubstituted alkyl, alkenyl or alkynyl group having up to 18 carbonatoms, preferably up to 8 carbon atoms, and especially up to 4 carbonatoms, for example, a methyl, ethyl, n-propyl, iso-propyl, n-butyl,sec-butyl, iso-butyl, tert-butyl, n-pentyl, n-hexyl, allyl, or vinylgroup.

An aliphatic group R, especially a methyl group, may be substituted by acycloalkyl, aryl or heterocyclic group, or R may itself represent acycloalkyl, aryl or heterocyclic group.

A cycloaliphatic group R may have up to 18 carbon atoms and is, forexample, a cyclopentyl, cyclohexyl or adamantyl group. An aryl group mayhave up to 12 carbon atoms and may have two or more fused rings. An arylgroup R is, for example, an unsubstituted or substituted phenyl group,and an unsubstituted or substituted aralkyl group is, for example, abenzyl, p-nitrobenzyl or benzhydryl group.

A heterocyclic group may have one or more heteroatoms, selected fromoxygen, nitrogen and sulphur, and up to 14 atoms in total. Aheterocyclic group is, for example, an oxygen-containing heterocyclicgroup, for example, a tetrahydropyranyl or phthalidyl group.

A stannyl group R may have up to 24 carbon atoms, for example, R mayrepresent a stannyl group having three substitutents, which may be thesame or different, selected from alkyl, alkenyl, cycloalkyl, aryl,aralkyl, alkoxy and aralkoxy groups, for example, alkyl groups having upto 4 carbon atoms, for example, n-butyl groups, phenyl and benzylgroups, especially three n-butyl groups.

A silyl group R may also have up to 24 carbon atoms and threesubstituents, which may be the same or different, selected from alkyl,alkenyl, cycloalkyl, aryl and aralkyl groups, for example, alkyl groupshaving up to 4 carbon atoms, for example, methyl and t-butyl groups.

Any group R that is capable of substitution may be substituted. Examplesof substituents are given above in relation to R². Substituents forphenyl groups are, for example, as described above in relation to R².

The group R may be removable by hydrolysis, by photolysis, by reductionor by enzyme action to give the free acid, or two or more methods may beused, for example, reduction followed by hydrolysis. A group R that maybe removed readily without substantial degradation of the rest of themolecule is particularly useful as a carboxyl protecting group. Examplesof esters that are readily split by reduction are arylmethyl esters, forexample, benzyl, p-nitrobenzyl, benzhydryl and trityl esters. Reductionof an ester, for example, an arylmethyl ester, may be carried out usinghydrogen and a metal catalyst, for example, a noble metal, for example,platinum, palladium or rhodium, which catalyst may be supported, forexample, on charcoal or kieselguhr.

Alternatively, a p-nitrobenzyl ester may be converted to the free acid,by a two-step method, with an initial reduction of the nitro group,followed by hydrolysis. The nitro group may be reduced by chemical orcatalytic reduction, for example, using a metal reducing agent, forexample, zinc in acetic acid, aqueous tetrahydrofuran or acetone. The pHshould be maintained within the range of from 3 to 6, preferably from 4to 5.5, preferably by the use of aqueous hydrochloric acid. Otherreducing agents are, for example, aluminum amalgam in a moist ether, forexample, tetrahydrofuran, and iron and ammonium chloride in an aqueousether, for example, aqueous tetrahydrofuran. Reduction of the nitrogroup is followed hy hydrolysis which may occur in situ during reductionof the nitro group or which may be carried out subsequently by treatmentwith an acid or a base. An o-nitrobenzyl ester may be converted to thefree acid by photolysis.

A stannyl ester, for example, a tri-n-butyl stannyl ester, may be splitreadily by hydrolysis, for example, by solvolysis, for example, usingwater, an alcohol, a phenol or a carboxylic acid, for example, aceticacid.

Certain ester groups may be split off by base hydrolysis, for example,acetylmethyl and acetoxymethyl ester groups.

There may be used an esterifying group that is removable underphysiological conditions, that is to say, the esterifying group is splitoff in vivo to give the free acid or the carboxylate, for example, anacyloxymethyl ester, e.g. an acetoxymethyl or pivaloyloxymethyl ester,an aminoalkanyloxymethyl ester, for example, an L-glycyloxymethyl,L-valyloxymethyl or L-leucyloxymethyl ester, or a phthalidyl ester, oran optionally substituted 2-aminoethyl ester, for example, a2-diethylamino-ethyl or 2-(1-morpholino)-ethyl ester.

Preferred esters are the p-nitrobenzyl, phthalidyl, pivaloyloxymethyl,acetylmethyl and acetoxy-methyl esters.

An ester of formula I, or of any other free acid described herein, maybe prepared by reaction with an alcohol, phenol or stannanol or areactive derivative thereof. The reaction is preferably carried outunder mild conditions in order to prevent rupture of the ring or ringsystem, for example, under neutral or mild acidic or basic conditions,and at temperatures within the range of from -70° to +35° C.

An alkyl, alkoxyalkyl or aralkyl ester may be prepared by reaction of anacid of formula I or any other free acid with the appropriatediazoalkane or diazoaralkane for example, diazomethane ordiphenyldiazomethane. The reaction is preferably carried out in anether, ester or halogenohydrocarbon as solvent, for example, in diethylether, ethyl acetate or dichloromethane. In general, temperatures belowroom temperature are preferred, for example, from -15° to +15° C.

An ester derived from an alcohol may also be produced by reaction of areactive derivative of the alcohol, for example, a halide, for example achloride, bromide or iodide, or a hydrocarbonsulphonyl derivative, forexample, a mesyl or tosyl ester, with a salt of an acid of formula I oranother free acid described herein for example, an alkali or alkalineearth metal salt, for example, a lithium, sodium, potassium, calcium orbarium salt or an amine salt, for example, a triethylammonium salt. Thisreaction is preferably carried out in a substituted sulphoxide or amidesolvent for example, in dimethylsulphoxide, dimethylformamide orhexamethylphosphoramide or, alternatively, an ester may be prepared byreaction of the acid with the alcohol in the presence of a condensingagent, for example, dicyclohexylcarbodiimide.

A stannyl ester may be formed by reaction of a carboxylic acid offormula I or another free acid described herein, or a salt thereof witha reactive tetravalent tin compound, especially a trialkyl tin oxide.

The present invention also provides the salts of those compounds offormula I that have salt-forming groups, especially the salts of freeacids of formula I and the acid addition salts of compounds of formula Ihaving a basic group. The salts are especially physiologically tolerablesalts, for example, alkali metal and alkaline earth metal salts, forexample, sodium potassium, lithium, calcium and magnesium salts,ammonium salts and salts with an appropriate organic amine; alsophysiologically tolerable acid addition salts. These may be formed, withsuitable inorganic and organic acids, for example, hydrochloric acid,sulphuric acid, carboxylic and organic sulphonic acids, for example,trifluoroacetic acid and p-toluene-sulphonic acid. Some compounds offormula I which contain a basic center may exist as Zwitterions; suchsalts are also part of this invention.

A salt of a free acid of formula I may be produced by reacting the freeacid with the appropriate base in a solvent, preferably under conditionsunder which the salt precipitates. In the case of an alkali metal salt,for example, a sodium or potassium salt, the preferred base is analkoxide.

A salt may be produced directly from an ester by splitting off the estergroup under suitable reaction conditions, for example, catalyticreduction of an ester, for example, a p-nitrobenzyl ester, in anaqueous/organic solvent, for example, comprising water and ethylacetate, dioxane, or tetrahydrofuran, in the presence of a metal salt,especially a bicarbonate, for example, in an equivalent amount or in aslight excess, yields a salt directly.

A compound of formula II may be prepared by a process which comprises

(i) allowing a compound of the general formula III ##STR8## in which Rand R² are as defined above, the two radicals R¹, which may be the sameor different, are each as defined above for R¹, and in which Ra, Rb, Rc,Rd and Re, which may be the same or different, each represents ahydrogen atom, an alkyl or alkenyl group having up to 8 and preferablyup to 4 carbon atoms, a cycloalkyl or cycloalkenyl group, a free oresterified carboxyl group, a halogen atom or a cyano group, and whereinany two of Ra to Re may form, together with the carbon atom or atoms toand through which they are attached, a cycloaliphatic ring containingfrom 3 to 10 carbon atoms, there being present zero, one or two of suchrings, and wherein Rc is cis or trans to Rd and the group ##STR9## iscis or trans to R² to react with a trivalent organophosphorus compoundto give a compound of formula II, or

(ii) reacting a compound of the general formula IV ##STR10## in which R,R¹ and R² are as defined above, with a trivalent organophosphoruscompound.

A compound of formula IV is preferably produced by effecting ringclosure in a compound of formula III as defined above.

Any of the interconversions (a) to (d) described above in relation tothe compound of formula I may be carried out on a compound of formulaII.

In the compound of formula III, the group ##STR11## is preferably one ofthe following: ##STR12## and especially the group --CH₂ --CH═CH₂.

Ring closure of the compound of formula III occurs spontaneously at roomtemperature, but the reaction is generally carried out at a temperaturewithin the range of from 20° to 150° C., preferably from 60° to 120° C.,and generally under an inert gas atmosphere, for example, under anatmosphere of nitrogen or argon. The cyclisation may be carried out in asolvent, which should be capable of achieving the desired temperature,for example, benzene toluene or dioxan.

The cyclisation is preferably carried out in the presence of an acid,which reduces significantly the reaction time. The acid may be a proticinorganic acid, a protic organic acid, or a Lewis acid. Examples ofprotic inorganic acids are sulphuric acid and phosphoric acid.

A protic organic acid may be a carboxylic acid, for example, formic acidor acetic acid, or a derivative thereof, for example, chloroacetic acid,dichloroacetic acid or, especially, trifluoroacetic acid. Sulphonicacids are further example of organic acids which may be present duringthe cyclisation of the compound of formula III. A sulphonic acid may bean alkyl sulphonic acid, for example, methanesulphonic acid or d- orl-camphor-10-sulphonic acid; or an aryl sulphonic acid, for example,benzenesulphonic acid, toluenesulphonic acid, benzenedisulphonic acid ora derivative thereof, for example, a chlorinated sulphonic acid.

A Lewis acid is, for example, boron trifluoride, boron trichloride,aluminium trichloride, titanium tetrachloride, tin tetrachloride, tindichloride, zinc chloride and zinc bromide.

Preferred acids are boron trifluoride, in the form of an etherate e.g.boron trifluoride diethyl etherate, and toluenesulphonic acid. Apreferred solvent is dioxan.

It is also preferable to carry out the cyclisation in the presence ofwater, a lower alkanol, or a mixture of any two or more selected fromwater and lower alkanols. The water, lower alkanol, or mixture thereofis preferably used in an amount of from 1 to 20 equivalents, calculatedon the compound of formula III. A lower alkanol is preferably methanol,ethanol or a propanol.

The water, lower alkanol or mixture thereof may be used either alone orin addition to the use of an acid.

It is thought that prior to cyclisation, the compound of formula IIIre-arranges to the compound of formula IIIa ##STR13##

The compound of formula III may be cyclised to give compound IV, whichis then treated with a trivalent organophosphorus compound, or thecompound of formula III may be converted into the corresponding compoundof formula II in one step. In the former case, the intermediate offormula IV may be isolated, or the treatment with the phosphine compoundmay be carried out in situ on the reaction mixture resulting from thecyclisation step.

The trivalent organophosphorus compound is especially one of the generalformula

    PR.sup.6 R.sup.7 R.sup.8

wherein R⁶, R⁷ or R⁸, which may be the same or different, eachrepresents an unsubstituted or substituted hydrocarbon group, forexample, a straight or branched chain aliphatic group for example, alkylgroup, an unsubstituted or substituted cycloaliphatic group for examplecyclopentyl or cyclohexyl group, an unsubstituted or substituted arylgroup for example, phenyl group; or an unsubstituted or substitutedhydrocarbon group in which one or more carbon atoms are replaced byhetero atoms, especially nitrogen, oxygen and sulphur atoms, forexample, alkoxy groups, amine groups, and aromatic and non-aromaticheterocyclic groups. Preferred tervalent organophosphorus compounds aretriphenylphosphine, tributylphosphine, trimethylphosphite andtriethylphosphite.

A further preferred group of tervalent organophosphorus compounds arethose in which, in PR⁶ R⁷ R⁸ one or more of the groups R⁶, R⁷ and R⁸comprises an insoluble polymer, which aids removal after the reaction.Generally one polymeric substituent is adequate. (See, for example, H.M. Relles, and R. W. Schluenz, J. Amer. Chem. Soc. 96 6469, (1974) andS. L. Regen and D. P. Lee, J. Org. Chem. 40, (11), 1669, (1975).

Another preferred group of trivalent organophosphorus compounds arethose in which, in PR⁶ R⁷ R⁸, one or more of the groups R⁶, R⁷ and R⁸comprise a cationic or anionic center, for example, a quaternaryammonium group or a carboxylate or sulphate group. The presence of acharged group assists removal of the resulting organophosphorussulphide, for example, by partition or by absorption on an insoluble ionexchange resin or by extraction into an aqueous solution at anappropriate pH, when the organophosphorus sulphide is water soluble.

The reaction of the compound of formula IV with the trivalentorganophosphorus compound is preferably carried out in a dry, inert,aprotic organic solvent or diluent, for example, an ether or an ester,for example, diethylether, tetrahydrofuran or ethyl acetate; an aromatichydrocarbon for example, benzene or toluene; a halogenated hydrocarbon,for example, methylene chloride or chloroform; or another organicsolvent, for example, dimethylformamide or acetonitrile. Preferredsolvents are methylene chloride and ethyl acetate. A mixture of two ormore solvents or diluents may be used. The reaction may be carried outat a temperature of from 0° to 80° C., preferably from 0° to 20° C., andit is preferable to use at least 1 equivalent of the phosphorus compoundper equivalent of the compound of formula IV.

The resulting compound of formula II may be isolated from the reactionmixture, for example, by chromatography or crystallisation. The compoundof formula II may be obtained as a mixture of the 5R- and 5S-isomers.These isomers can be separated by known methods, if desired, or thecompound of formula II can be used in the form of an isomeric mixture.The preferred stereochemistry in compound II is generally that ofnatural penicillins and cephalosporins i.e. 5R.

If R in formula II represents an esterifying group, this may be removedin the usual manner, depending on the nature of the ester group, forexample, by hydrolysis, reduction, or enzymatically, to yield the freeacid. A free acid or an ester may be converted into a salt, especially aphysiologically tolerable salt, or a salt may be converted into anothersalt or the free acid or an ester. An ester may be transesterified, or afree acid converted into an ester, for example, to give an ester capableof removal under physiological conditions. Examples of such proceduresare given above.

A compound of the general formula II may be produced in various ways,for example, as shown in the reaction scheme below, in which ##STR14##in which Ra to Re are as defined above. ##STR15## in which

R, R¹ and R² are as defined above,

Δ denotes that a reaction requires uptake of heat from an externalsource,

Y represents a group that is capable of being replaced by a nucleophilicgroup and is, for example, a halogen atom, for example, a chlorine,bromine or iodine atom, or a substituted, activated hydroxy group, forexample, a sulphonyloxy group, for example, a radical of the formula

    --OSO.sub.2 R.sup.9

in which R⁹ represents an aliphatic, cycloaliphatic, aryl or araliphaticgroup having up to 18 carbon atoms, which may be substituted orunsubstituted, for example, as described above for R². An aliphaticgroup R⁹ is, for example, an alkyl group having up to 8 carbon atomswhich may be substituted by one or more halogen atoms, for example,chlorine and bromine atoms. An aryl group R⁹ has, for example, up to 15carbon atoms, and may be substituted by one or more substituents, whichmay be the same or different, selected from alkyl and alkoxy groups, forexample, methyl and methoxy groups, nitro groups, and halogen atoms,especially bromine atoms, R⁹ preferably represents an unsubstituted orsubstituted aryl group having up to 18 carbon atoms, for example, aphenyl, p-tolyl, p-bromophenyl or p-nitrophenyl group, or anunsubstituted or substituted alkyl group, especially with 1 to 4 carbonatoms, and preferably a methyl or trifluoromethyl group.

Y preferably represents a bromine or iodine atom or a methylsulphonate,trifluoromethylsulphonate, tolylsulphonate or benzenesulphonate group.

Y¹ represents a group that is capable of being replaced by anucleophilic group and is, for example, especially an activated hydroxygroup, more especially, an acyloxy group, for example, an acetoxy group,or a sulphonyl group, for example, of the formula --SO₂ R_(a) ⁹ in whichR_(a) ⁹ represents an alkyl group having from 1 to 4 carbon atoms, anaryl group, for example, a phenyl group, or

Y¹ represents a halogen atom, for example, a chlorine or bromine atom.

A compound of formula VIII may be prepared as described in, for example,Liebigs Annalen Chemie 1974, pp. 539-560, Claus, Grimm and Prossel;DT-OS 1 906 401; UK Specification No. 2 013 674; Japanese PublishedApplication JA No. 80641; or H. R. Pfaendler, J. Gosteli and R. B.Woodward, J.A.C.S. 102:6 (1980), 2039-2043; Belgian Patent SpecificationNo. 882.764. A compound of formula VIII may be converted into a compoundof Formula VII by reaction with a compound of formula ##STR16## in whichR¹⁰ represents a hydrogen atom or an alkali metal atom especially asodium or potassium atom, and Ra to Re are as defined above.

The reaction is generally carried out in a solvent, preferably a proticsolvent, for example, water or an alcohol, or a non-protic,water-miscible solvent which is preferably polar, for example, dimethylformamide, dimethyl sulphoxide, tetrahydrofuran or dioxane. The reactiontemperature is, for example, from -20° to +100° C., preferably from -10°to +20° C.

A compound of formula VII may be reacted with a compound of formula IX

    YCH.sub.2 CO.sub.2 R                                       IX

in which Y and R are as defined above in the presence of a base, to givea compound of formula VI.

The base may be inorganic, organic or organometallic, for example, analkali metal or alkaline earth metal hydroxide, oxide, carbonate,bicarbonate or hydride, for example, sodium hydroxide, magnesium oxide,potassium carbonate, potassium bicarbonate or sodium hydride; an amine,for example, a dialkylamine or trialkylamine, for example,triethylamine, dabco (diazabicyclo(2,2,2)octane), pyridine, or analkyl-substituted or amino-substituted or dialkylamino-substitutedpyridine for example, N,N-dimethylaminopyridine, or collidine; aguanidine, for example, tetramethylguanidine; DBN (diazabicyclononene)or DBU (diazabicycloundecene), a polymeric base i.e. a base attached toan inert polymeric support e.g. Hunig's base (diisopropylethylamineattached to polystyrene); a metallated amine, for example, a metallatedalkyl or arylamine, for example, lithium diisopropylamide (LDA), lithiumhexamethyldisilazide, lithium piperidide, lithium2,2,6,6-tetramethylpiperidide, or a Grignard reagent. Preferred basesare, for example, potassium carbonate, sodium hydride, lithiumdiisopropylamide and triethylamine.

The reaction is generally carried out in a solvent or diluent that isinert under the reaction conditions, for example, an amide, for example,dimethylformamide, dimethylacetamide or hexamethylphosphoramide; ahydrocarbon, for example, benzene or toluene; an inert, aprotic solventor diluent, for example, an ester, for example, ethyl acetate, or anether, for example, diethylether, tetrahydrofuran or dioxan; oracetonitrile, nitromethane, dimethyl-sulphoxide, or sulpholane.Dimethylformamide and dimethylacetamide are preferred. A mixture of twoor more solvents and/or diluents may be used.

The reaction may be carried out at a temperature within the range offrom -80° C. to the reflux point of the reaction mixture, preferablyfrom -40° to +50° C., and especially from -20° to +30° C.

From 1 to 1.5 moles of compound IX are preferably used per mole ofcompound VII, especially from 1 to 1.1 mole of IX per mole of VII. Thebase is used in an amount for example, from 1 to 4 moles of base permole of compound VII.

The reaction is preferably carried out by dissolving compound VII in asolvent, advantageously in dimethylformamide with stirring, adding thebase, adding the compound of formula IX and reacting at the desiredtemperature. The resulting compound of formula VI may be worked up andisolated in the usual manner, for example, using chromatographic and/orcrystallisation techniques, or the subsequent reaction may be carriedout directly on the resulting reaction mixture after removal of anysolvent that is not compatible with the subsequent reaction.

If R in formula VI represents a carboxyl esterifying group, this groupmay be converted into another esterifying group R, for example, tointroduce a group R that is more easily removable under desiredconditions. This transesterification is generally carried out asfollows: the ester of formula VI is hydrolysed in known manner using,for example, acid or alkaline hydrolysis, preferably an alkali metalhydroxide, especially sodium or potassium hydroxide. The ester offormula VI for example, a methyl ester, is preferably hydrolysed usingan alkali metal hydroxide especially one mole thereof per mole of theester of formula VI in a solvent, for example ethanol, methanol orwater, or an aqueous-organic solvent, for example,tetrahydrofuran/water, ethanol/water, or acetonitrile/water.

The reaction mixture is then generally acidified, and the free acid ispreferably isolated and, if desired, the free acid is then esterifiedwith an esterifying agent capable of introducing a different esterifyinggroup R, for example with an alcohol ROH in the presence of an acid oranother activating agent, for example, dicyclohexylcarbodiimide, or withan alkylating agent RY in which Y is as defined above. Esterificationmethods are described above in relation to the compound of formula I.

Transesterification may be carried out on compound VI as describedabove, or on any other intermediate or on the final product of formulaI.

As indicated in the reaction scheme above, compound VI may be convertedto compound III by the addition of the group ##STR17## to the side chainattached to the nitrogen atom, followed by oxidation of the sulphur atomattached to position 3 of the azetidinone ring.

A compound of formula VI may be converted into a compound of formula Vby treatment with a base in the presence of carbon disulphide followedby reaction with an acylating agent, or by treatment with a base, thenwith carbon disulphide, and finally reaction with an acylating agent. Anacylating agent is generally an activated carboxylic acid.

The activated carboxylic acid may be any activated acid derivativecomprising the group R¹. Such derivatives are well known in the art, andinclude acid chlorides, acid anhydrides, and activated esters.

An anhydride may be symmetrical or asymmetrical. An activated acid maycomprise an unsubstituted or substituted carbonic, sulphonic orphosphoric ester group.

The acylating agent may have the general formula X

    R.sup.1 COZ                                                X

in which Z represents a halogen atom, especially a chlorine atom,--OCOR¹¹ in which R¹¹ is as defined for R¹ and may be the same as R¹ ordifferent, --O₂ COR¹² or --OSO₂ R¹², in which R¹² is as defined abovefor R⁹, ##STR18## in which R¹³ and R¹⁴, which may be the same ordifferent, each represents an unsubstituted or substituted alkyl, arylor aralkyl group, or R¹³ and R¹⁴ together with the phosphorus atom mayform a 5- or 6-membered ring, or either or both of R¹³ and R¹⁴ mayrepresent a group --OR_(a) ¹³ or --OR_(a) ¹⁴ respectively, in whichR_(a) ¹³ and R_(a) ¹⁴ are as defined above for R¹³ and R¹⁴ respectivelyand, in the case when R¹³ represents --OR_(a) ¹³ and R¹⁴ represents--OR_(a) ¹⁴, R_(a) ¹³ and R_(a) ¹⁴ may together represent a 5- or6-membered ring.

The compound of formula VI is preferably reacted first with a base, thenwith carbon disulphide, and then finally with the acylating agent.

The base preferably has a pK≧20, and is preferably a metallated amine.Examples of preferred bases are lithium diisopropylamide, lithium2,2,6,6-tetramethylpiperidide, lithium cyclohexyl isopropylamide,lithium hexamethyl disilazide, and sodamide.

The reaction is generally carried out in an inert solvent, for example,an oxygenated hydrocarbon, preferably an ether, for example, diethylether, tetrahydrofuran, dioxane, glyme or diglyme. The reactiontemperature is, for example, from -120° to +30° C., preferably from-100° to -20° C.

The amount of base used is for example, from 1 to 4 moles, calculatedper mole of compound VI, preferably from 2.0 to 3.0 moles of base.Carbon disulphide is preferably used in an amount of from 1 to 5 moles,especially from 2 to 3 moles, per mole of compound VI.

The reaction is preferably carried out as follows: to a stirred solutionof compound VI under an inert atmosphere is added the base then asolution of carbon disulphide in the same or a different solvent andfinally the acylating agent to complete the reaction.

There may then be admixed a protic source having a pK less than 10, andespecially from 5 to 2, for example, acetic, citric, oxalic or formicacid.

Oxidation of the resulting compound V may be carried out by any methodcapable of converting a sulphide into a sulphoxide, for example, theremay be used an oxidising agent, for example, hydrogen peroxide, aperiodate e.g. sodium periodate, ozone, a peracid e.g. peracetic acid orperbenzoic acid, a substituted perbenzoic acid e.g. m-chloroperbenzoicacid, or a permanganate salt, e.g. potassium permanganate. Preferredoxidising agents are hydrogen peroxide and m-chloroperbenzoic acid. Overoxidation should be avoided, for example, by using only one equivalentof a peracid.

The oxidation is preferably conducted in an inert solvent at a preferredtemperature of from -40° to +30° C. Preferred solvents are ethylacetate, methylene chloride, chloroform, acetonitrile, and loweralcohols, for example methanol and ethanol.

The resulting compound of formula III may be isolated and worked upusing known methods.

It is advisable to esterify a free carboxyl group in a compound offormula III prior to cyclisation. Although an ester group may beintroduced immediately prior to cyclisation, it is preferable toesterify the carboxyl group at an earlier stage in the preferredreaction sequence, for example, to esterify a free carboxyl group in acompound of formula V or VI to ensure that the carboxyl group does nottake part in any of the subsequent reactions. An esterifying group maybe transesterified to another ester group having more desirableproperties for a particular stage of the reaction sequence.

Furthermore, it is advisable to protect any reactive moiety present inany of R, R¹ and R² so that such a moiety does not take part in anysubsequent reaction. Examples of such moieties are hydroxy, carboxy andamine moieties. Groups suitable for protecting such reactive moietiesare well known, as are methods for their removal. (cf Protective Groupsin Organic Chemistry, editor J. F. W. McOmie, Plenum Press, 1973).

Examples of groups suitable for protecting hydroxyl moieties aretetrahydropyranyl groups, methoxyethoxymethyl groups, acyl groups, forexample, acetyl, chloroacetyl and formyl groups, and silyl groups, forexample as described above for R, for example, trimethyl silyl andt-butyl-dimethylsilyl groups. Carboxy protecting groups are, forexample, as described above for R. Amino protecting groups are, forexample, t-butyloxycarbonyl, benzyloxycarbonyl,p-nitrobenzyloxycarbonyl, p-nitrobenzenesulphenyl and trityl groups.

Reactive moieties may be protected at any appropriate point in thereaction sequence, and the protective groups and preferably removedduring or after the formation of the compound of formula I.

In a compound of formula II any one or more of the above steps (a), to(d) may be carried out, if appropriate, before conversion to a compoundof formula I.

At each stage of the preferred reaction sequence, the desired compoundmay be isolated from the reaction mixture and, if desired, purified byappropriate techniques generally used for the purification of organiccompounds, for example, chromatography or crystallisation.

As indicated above, various intermediates may be produced in the form ofmixtures of isomers of various kinds. Such a mixture may be separated orresolved at any stage, or the isomeric mixture may be used per se forsubsequent reactions.

All of the compounds that are provided by the invention may exist in anyappropriate isomeric form, as discussed above, either as a pure isomeror as a mixture of any two or more isomers.

A compound of the general formula I may exist in the tautomeric forms offormulae Ia and Ib, and each of these forms may have the R or Sstereochemistry indepentently at positions 5 and 6 and also, in formulaIa, at position 2. Further isomeric forms will occur when anysubstituent contains a chiral atom. Any mixture of any two or moreisomeric forms may be resolved, if desired, and/or an isomeric mixturemay be prepared.

The compounds of the general formula I are particularly useful in thesynthesis of substituted penems. For this purpose the compound offormula I are reacted in an inert solvent in the presence of an excessof a base, preferably 1 to 2 equivalents and an excess of an alkylatingagent, preferably 1 to 3 equivalents.

Preferred bases are organic bases such as secondary or tertiaryalkylamines, e.g. triethylamine, diisopropylamine,ethyl-diisopropylamine or inorganic bases such as Na₂ CO₃, K₂ CO₃,NaHCO₃. Preferred alkylating agents are alkyl halides preferablybrominated or iodinated lower alkyls.

The reaction is carried out in an appropriate solvent such astetrahydrofuran, dioxane, ethylacetate, methylene chloride, chloroform,dimethylformamide.

The preferred reaction temperature is 0° to 40° C.

The compounds of formula I and salts thereof are β-lactamase inhibitors,and the compounds are generally stable to the action of β-lactamasesproduced by gram positive organisms, for example, by Staphylococcusaureus and gram negative organisms, for example, Enterobactercloacae.They also possess antibacterial properties themselves and may be used inhumans and other animals, for example, to treat bacterial infectionscaused by gram positive and gram negative bacteria, for example,Staphylococcus aureus, Streptomyces pyogenes, Bacillus subtilis, E.coli, Pseudomonas aeruginosa, and Proteus inorganii, some strains ofwhich are pencillin-resistant.

The invention accordingly provides a pharmaceutical preparation whichcomprises a compound of formula I or a physiologically tolerable salt ofa compound of formula I or a mixture of two or more such substances, asactive ingredient, in admixture or conjunction with a pharmaceuticallysuitable carrier. The preparation may also comprise one or more otherpharmaceutically active substances, for example, another antibacterialsubstance, especially one which has a β-lactam ring. The preparation maybe in a form suitable for enteral or parenteral administration, forexample, for oral, intravenous, or intramuscular administration, forexample, as tablets, capsules, syrups, or sterile injectable orinfusible solutions. The preparations are advantageously in unit dosageform and preferably comprise from 10 to 2000 mg of the activeingredient. The daily dosage of the active substance is generally from20 to 8000 mg, in divided doses, generally up to 4 doses.

The invention also provides the use of an active compound as definedabove as a β-lactamase inhibitor and/or as an antibacterial agent.

The invention further provides a pharmaceutical preparation whichcomprises an active compound as defined above, or a physiologicallytolerable salt thereof, or a mixture of two or more such substances, inunit dosage form.

The invention also provides a pharmaceutical preparation which comprisesan active compound as defined above, or a physiologically tolerable saltthereof or a mixture of two or more such substances, and one or morefurther pharmaceutically active substances, for example, as describedabove and, for example, in unit dosage form.

Unit dosages are preferably as described above.

The following Examples illustrate the invention. In them, temperaturesare expressed in degrees Celsius.

EXAMPLE 1 4-Allylthioazetidin-2-one ##STR19##

A solution of 42.9 g of sodium hydroxide in 500 ml of water was made upunder nitrogen and cooled to room temperature, 108 ml of allyl mercaptanwere added and the mixture stirred under nitrogen for 30 minutes. 138.7g of 4-acetoxyazetidin-2-one were added to the mixture over 10 minutesunder nitrogen and the reaction mixture was stirred overnight. Thereaction was checked for completion by T.L.C. (hexane-ethyl acetate) andextracted into dichloromethane (6×250 ml). The organic layer was washedwith water (2×250 ml), dried over magnesium sulphate and evaporated invacuo to dryness. Purification, over silica gel and elution withhexane-ethyl acetate afforded the above product as a yellow oil. (112.1g, 73% of the theoretical yield).

υ_(max) =1769, 1778 (sh) cm⁻¹.

δ(CDCl₃) 2.86 (1H, ddd, J_(NH),3β 1.5 Hz, J4,3β3 Hz, J₃α,3β 15 Hz,3β-H), 3.28 (2H, d, J 7 Hz, S--CH₂), 3.37 (1H, ddd, J_(NH),3α 1.5 Hz,J₄,3α 6 Hz, J₃β,3α 15 Hz, 6α-H), 4.71 (1H, dd, J₃β,4 3 Hz, J₃α,4 6 Hz,4-H), 4.93-5.38 (2H, m, ═CH₂), 5.49-6.24 (1H, m, CH═), 7.43 (1H, bs,NH).

m/e 143.0405 (M+).

EXAMPLE 2 4'-Nitrobenzyl 2-(4-allylthioazetidin-2-on-1-yl)acetate##STR20##

11.5 g of 4-nitrobenzylbromoacetate in 30 ml of dimethylformamide wereadded to 5.0 g of 4-allylthioazetidin-2-one dissolved in 70 ml ofdimethylformamide with stirring under argon at room temperature. After 5mins, 10.61 g of potassium carbonate were added to the solution. Duringthe following 20 mins there was a color change in the mixture fromyellow to dark brown. Stirring was continued for a further 3 hrs 40 minswhen TLC analysis indicated completion of reaction. The mixture waspoured into water (300 ml), extracted into ethyl acetate (4×100 ml) andthe combined organic extracts washed with water (3×200 ml). The organiclayer was dried with MgSO₄ and evaporated to leave a yellow oil.

The crude product was chromatographed on silica gel using ethylacetate/hexane mixtures as eluant. 5.89 g of product was obtained (50%of the theoretical yield).

δ(CDCl₃) 3.05 (1H,2d,J trans 3 Hz,3-H), 3.17 (1H,S,S--CH₂ --), 3.30(1H,S, S--CH₂), 3.53 (1H,2d,J cis 5 Hz, J gem 15 Hz, 3-H), 3.84 and 4.38(2H,ABq,J18 Hz,--N--CH₂ --), 4.95 (1H,2d,4-H), 5.00-5,34 (2H,m, ═CH₂),5.34 (2H,S,--O--CH₂), 5.54-6.40 (1H,m, ═CH), 7.53-8.38 (4H,m,--C₆ H₄)

ν_(max) (CDCl₃) 1769,1758 cm⁻¹

m/e 336.0525 (M⁺), 295.0391 (M--CH₂ CHCH₂), 136.0385 (base peak)

EXAMPLE 3 Methyl 2-(4-allylthioazetidin-2-on-1-yl)acetate ##STR21##

21.8 ml of methyl bromoacetate in 220 ml of dimethylformamide were addedto 31.1 g of 4-allylthioazetidin-2-one dissolved in 420 ml ofdimethylformamide, with stirring, under argon, at room temperature.After 5 mins, 66.0 g of anhydrous potassium carbonate were added to thesolution. The suspension was then stirred for a further 18 hours.

The mixture was poured into water (2.5 l), extracted into ethyl acetate(3×1200 ml) and washed with water (3×2 l). The organic layer was driedwith MgSO₄ and evaporated to leave a yellow oil.

The crude product was chromatographed on silica gel using ethylacetate/hexane mixtures as eluant, 22.0 g of the above product wasobtained. (47% of the theoretical yield)

δ(CDCl₃) 2.97 (1H,2d,J trans 3 Hz,3-H), 3.16 (1H,S, S--CH₂ --), 3.26(1H,S, S--CH₂ --), 3.45 (1H,2s,J cis 5 Hz,J gem 15 Hz, 3-H), 3.66 and4.23 (2H,ABq,J 17 Hz,--N--CH₂ --), 3.72 (3H,S,CH₃), 4.86 (1H,2d,4-H),4.95-5.27 (2H,m, ═CH₂), 5.50-6.15 (1H,m, ═CH)

ν_(max) (CHCl₃) 1766, 1749 cm⁻¹

m/e 215,0539 (M⁺), 142.0456 (base peak)

EXAMPLE 4 Methyl 2-(4-allylthioazetidin-2-on-1-yl)acetate ##STR22##

0.070 ml of methylbromoacetate in 1 ml of dimethylformamide was added to0.100 g of 4-allylthioazetidin-2-one dissolved in 2 ml ofdimethylformamide with stirring under argon at 0°. After 5 mins, 0.040 gof hexane washed sodium hydride, was added to the solution. The coolingbath was removed and stirring continued for a further 45 mins, when TLCanalysis indicated completion of reaction.

The mixture was poured into water (15 ml), extracted into ethyl acetate(2×12 ml) and washed with water (3×15 ml). The organic layer was driedwith MgSO₄ and evaporated to leave a yellow oil.

Yield: 0.089 g, (59% of the theoretical yield).

(For spectral data see Example 3)

EXAMPLE 5 2-(4-Allylthioazetidin-2-on-1-yl)acetic acid ##STR23##

2.34 g of potassium hydroxide dissolved in a mixture of 285 ml ofethanol and 15 ml of water were added to 6.0 g of methyl2-(4-allylthioazetidin-2-on-1-yl) acetate with stirring at roomtemperature. The solution was poured into 720 ml 1M hydrochloric acid,extracted into dichloromethane (2.650 ml), the organic layer extractedwith saturated sodium bicarbonate solution and the aqueous phaseacidified to pH1 with 5M hydrochloric acid. This solution was extractedinto dichloromethane (5×650 ml), dried with MgSO₄ and evaporated toleave a colorless oil.

Yield: 5.37 g (96%) δ(CDCl₃) 3.06 (1H,2d,J trans 3 Hz,3-H), 3.19 (1H,S,S--CH₂ --), 3.30 (1H,S,S--CH₂), 3.53 (1H,2d,J cis 5 Hz,J gem 16 Hz,3-H),3.75 and 4.36 (2H,ABq,J18 Hz,N--CH₂ --), 4.96 (1H,2d,4-H), 5.03-5.34(2H,m, ═CH₂), 5.58-626 (1H,m,H--C═)

ν_(max) (CDCl₃) 1765, 1730 cm⁻¹

m/e 201.0500 (M⁺), 86.0239 (base peak).

EXAMPLE 6 Pivaloyloxymethyl 2-(4-allylthioazetidin-2-on-1-yl)-2-acetate##STR24##

To a solution of 14 mls of diisopropylamine and 20.4 g of2-(4-allylthioazetidin-2-on-1-yl) acid in 450 ml of dimethylformamide,at 0° C., were added dropwise 14 ml of chloromethylpivalate. Thesolution was warmed to room temperature and stirred for 5 days until TLCanalysis (silica gel: hexane-ethyl acetate) showed absence of startingmaterial. The reaction mixture was poured into water (500 ml), andextracted into ethyl acetate (3×500 ml); the organic layer was washedwith hydrochloric acid (pH 2.0, 400 ml), then water (2×500 ml), driedover magnesium sulphate and evaporated to dryness. The crude product waspurified over silica gel eluting with hexaneethyl acetate to give theabove product as a pale yellow oil (20.1 g, 63%).

ν_(max) =1760, 1768, 1776 cm⁻¹

δ(CDCL₃) 1.20 (9H, s. C(CH₃)₃, 2.99 (1H, dd, J₄,3β 3 Hz J₃α,3β 16 Hz,3β-H), 3.27 (2H, d, J 7 Hz, S--CH_(z)), 3.53 (1H, dd, J₄,3α 5 Hz, J₃β,3α16 Hz, 3α--H), 4.08 (2H, q, J 18 Hz, N--CH₂), 4.93 (1H, dd, J₃α,4 5 Hz,J₃β,4 3 Hz, 4-H), 5.03-5.50 (2H, m, ═CH₂), 5.57-6.23 (1H, m, CH═), 6.80(2H, 3,CO₂ CH₂)

EXAMPLE 7 Methyl 3,3-di(acetylthio)-2-(4-allylthioazetidin-2-on-1-yl)propenoate ##STR25## EXAMPLE 7a

A solution of lithium hexamethyldisilazide was prepared by the additionof 5.12 ml of a 1.6M solution of n-butyllithium in hexane to 1.75 ml ofhexamethyldisilazane in 25 ml of dry THF at -10° with stirring, underargon. The solution was cooled to -78° and added to 1.0 g of methyl2-(4-allylthioazetidin-2-on-1-yl)acetate in 12 ml of dry tetrahydrofuranat -78°, with stirring, under argon. After 5 min, 0.846 ml of carbondisulphide was added by syringe. 1.77 ml of acetic anhydride were thenadded, followed by 1.07 ml of glacial acetic acid. The solution wasallowed to warm to room temperature and evaporated to leave a yellowoil.

The crude product was chromatographed on silica gel using ethylacetate/hexane mixtures as eluant. 1.14 g (66%) of the above product wasobtained.

δ(CDCl₃) 2.38 (6H,S, ##STR26## 3.17 (1H, 2d, J trans 3 Hz, 3-H), 3.35(1H,S,S--CH₂ --), 3.45 (1H,S, S--CH₂ --), 3.43-3.78 (1H,2d,J gem 15 Hz,3-H), 3.86 (3H,S, --O--CH₃), 5.06-5.45 (3H,m,═CH₂,4-H), 5.63-638(1H,m,═CH)

ν_(max) 1786, 1740, 1715 cm⁻¹ ##STR27##

43(COCH₃) (base peak)

EXAMPLE 7b

A solution of lithium hexamethyldisilazide was prepared by the additionof 32.9 ml of a 1.6M solution of n-butyllithium in hexane to 11.25 ml ofhexamethyldisilazane in 125 ml of dry THF at -10° with stirring, underargon. The solution was cooled to -78° and added to 5.0 g of methyl2-(4-allylthioazetidin-2-on-1-yl)acetate in 60 ml of dry tetrahydrofuranat -78°, with stirring, under argon. After 5 min, 4.23 ml of carbondisulphide was added by syringe. 885 ml of acetic anhydride were thenadded. The solution was allowed to warm to room temperature andevaporated to leave a yellow oil.

The crude product was purified by extraction using chloroform and water,and the resulting organic phase was evaporated to give a yellow oil,having the characteristics given in Example 7a.

EXAMPLE 8 Methyl3,3-di(acetylthio)2-(4-allylsulphinylazetidin-2-on-1-yl)propenoate##STR28## EXAMPLE 8a

0.549 g of 3-chloroperbenzoic acid (81% pure) in 7 ml of ethyl acetate(7 ml) was added dropwise over 20 mins to a stirred solution of 0.939 gof methyl 3,3-di(acetylthio)-2-(4-allylthioazetidin-2-on-1-yl)propenoatein 18 ml of ethyl acetate at -35° C. The solution was evaporated todryness, slurried with dichloromethane and chromatographed on silica gelusing ethyl acetate/hexane mixtures as eluant. 0.659 g (67%) of theabove product was obtained.

δ(CDCl₃) 2.38 (3H,S--C--CH₃), 2.42 (3H,S--C--CH₃) 3.06-3.70(4H,m,3-H,S--CH₂ --), 3.87 (3H,S,--O--CH₃), 5.24-6.55 (4H,m,HC═CH₂,4-H).

ν_(max) (CDCl₃) 1796, 1730 cm⁻¹ ##STR29##

EXAMPLE 8b

5.50 g of 3-chloroperbenzoic acid in 30 ml of ethyl acetate were addeddropwise over 30 mins to a stirred solution of the methyl3,3-di(acetylthio-2-(4-allylthioazetidin-2-on-1-yl)propenoate obtainedin Example 7b, in 50 ml of ethyl acetate at -35° C. The solution wasevaporated to dryness, slurried with dichloromethane and chromatographedon silica gel using ethyl acetate/hexane mixtures as eluant. 6.26 g ofthe title product were obtained. (69% of the theoretical yield,calculated on the starting material of Example 7b. Analytical data as inExample 8a).

EXAMPLE 9 Methyl3-acetylthio-8-oxo-4,5-dithia-1-azabicyclo[4,2,0]oct-2-ene-2-carboxylate##STR30## EXAMPLE 9a

0.050 g of methyl3,3-di(acetylthio)-2-(4-allylsulphinylazetidin-2-on-1-yl)propenoate wasrefluxed in 5 ml of dioxan until TLC analysis indicated completeconsumption of starting material (3 hrs). The crude product waschromatographed on silica gel using ethyl acetate/hexane mixtures aseluant. 0.009 g (24%) of the above product was obtained.

δ(CDCl₃) 2.44 (3H,S, ##STR31## 3.15 (1H,2d,J trans 3 Hz, 7-H), 3.88(1H,2d,J cis 5 Hz,J gem 17 Hz,7-H), 3.90(3H, S,--O--CH₃), 4.89(1H,2d,6-H)

ν_(max) (CDCl₃) 1794, 1739 cm⁻¹

m/e 290.9743 (M⁺), 43.0211 (base peak).

EXAMPLE 9b

0.250 g of methyl3,3-di(acetylthio)-2-(4-allylsulphinylazetidin-2-on-1-yl)propenoate and80.2 μl of boron trifluoride diethyl etherate were refluxed in 12 ml ofdioxan for 40 minutes, when TLC analysis indicated complete consumptionof starting material. The crude product was evaporated to dryness andchromatographed on silica gel using ethyl acetate/hexane mixtures aseluant. 0.090 g (48%) of the title product was obtained.

EXAMPLE 9c

0.500 g of methyl 3,3-di(acetylthio)-2-(4-allylsulphinylazetidin-2-on-1-yl)-propenoate and 0.242 g of4-toluenesulphonic acid hydrate were heated under reflux in 25 ml ofdioxan for 40 minutes, when TLC analysis indicated complete consumptionof the starting material. Purification of the crude product was carriedout as described in Example 9b. 0.120 g (32%), of the purified productwas obtained.

EXAMPLE 9d

The procedure described in Example 9c was carried out, substituting 0.30ml of trifluoroacetic acid for the 0.242 g of 4-toluenesulphonic acidhydrate, and refluxing for 2 hours. 0.064 g of purified product wasobtained (17% of the theoretical yield).

EXAMPLE 10 Methyl3-acetylthio-7-oxo-4-thia-1-azabicyclo[3,2,0]hept-2-ene-2-carboxylate##STR32##

0.064 g of methyl3-acetylthio-8-oxo-4,5-dithia-1-azabicyclo[4,2,0]oct-2-ene-2-carboxylatewas dissolved in 1 ml of deuterochloroform and 0.063 g oftriphenylphosphine added. TLC and NMR analysis indicated completeconversion of starting material to product. The crude product waschromatographed on silica gel using ethyl acetate/hexane as eluant togive 0.035 g (61%) of purified product.

δ(CDCl₃) 2.47 (3H,S, ##STR33## 3.15-4.05 (5H,m,J trans 2 Hz, J_(cis) 4Hz, J_(gem) 17 Hz, --O--CH₃, 6-H), 3.85 (3H,S,--O--CH₃), 5.73(1H,2d,5-H)

ν_(max) (CDCl₃) 1798, 1710 cm⁻¹

m/e 258.9970 (M⁺), 174.9745 (base peak)

EXAMPLE 11 Pivaloyloxymethyl3,3-di(acetylthio)-2-(4-allylthioazetidin-2-on-1-yl)propenoate ##STR34##

A solution of lithium hexamethyldisilazide was prepared by the additionof 3.53 ml of a 1.6M solution of n-butyllithium in hexane to 1.19 ml ofhexamethyldisilazane in 25 ml of dry tetrahydrofuran at -10° withstirring under argon. The solution was cooled to -78° and added bycannula to 1.02 g of pivaloyloxymethyl2-(4-allylthioazetidin-2-on-1-yl)acetate in 10 ml of dry tetrahydrofuranat -78° with stirring under argon.

After 5 minutes 582 μl of carbon disulphide were added by syringe. After15 minutes, 1.22 ml of acetic anhydride were added followed by 0.74 mlof glacial acetic acid. The solution was allowed to warm to roomtemperature and the tetrahydrofuran solvent was removed by evaporationto leave an oily residue.

The crude product was chromatographed on silica gel using ethylacetate/hexane mixtures as eluant. 0.755 g (49%) of purified product wasobtained.

δ(CDCl₃) 1.25 (9H,S, C(CH₃)₃), 2.28 (6H,S, ##STR35## 3.0-3.7 (4H,m,3-Hand S--CH₂ --), 5.0-6.1 (6H,m,4-H and --CH═CH₂ and O--CH₂ --)

ν_(max) (CDCl₃) 1784, 1758, 1746(sh), 1720(sh) cm⁻¹

EXAMPLE 12 Pivaloyloxymethyl3,3-di(acetylthio)-2-(4-allylsulphinylazetin-2-on-1-yl)propenoate##STR36##

363 mg of 3-chloroperbenzoic acid in 3 ml of ethyl acetate were addedportion wise to a stirred solution of 673 mg of pivaloyloxymethyl3,3-di(acetylthio)-2-(4-allylthioazetidin-2-on-1-yl)propenoate in 10 mlof ethyl acetate. The solution was then allowed to warm to roomtemperature, evaporated to dryness and chromatographed on silica gelusing ethyl acetate/hexane mixtures as eluant. The product was obtainedas a mixture of R and S sulphoxides which are partially separated duringthe chromatography. Total yield of product, a yellow oil, was 0.502 g(72%).

δ(CDCl₃) 1.24 (9H,S,CMe₃), 2.42 (6H,S, ##STR37## 3.0-4.0 (4H,m,3-H andS--CH₂ --), 5.2-61. (6H,m, 4-H and --CH═CH₂ and O--CH₂ --)

ν_(max) (CDCl₃) 1791, 1750 cm⁻¹

EXAMPLE 13 Pivaloyloxymethyl3-acetylthio-8-oxo-4,5-dithia-1-azabicyclo[4,2,0]oct-2-ene-2-carboxylate##STR38##

A solution of 82 mg of pivaloyloxymethyl3,3-di(acetylthio)-2-(4-allylsulphinylazetidin-2-on-1-yl)propenoate and32 mg of 4-toluenesulphonic acid hydrate in 10 ml of dioxane was heatedrapidly to reflux and maintained under reflux for 1 hour. The solventwas removed by evaporation and the residue chromatographed on silica gelusing ethyl acetate/hexane mixtures as eluant. The product (35 mg, 54%)was obtained as a yellow oil.

δ(CDCl₃) 1.25 (9H,S,C(CH₃)₃), 1.61 (3H,S, ##STR39## 3.1 (1H,2d,J_(trans)3 Hz, 7-H), 3.88 (1H, 2d, J_(cis) 5 Hz, J_(gem) 16 Hz, 7-H), 5.87(2H,S,--OCH₂ --), 4.83 (1H,2d,6-H).

ν(CDCl₃) 1796, 1757 cm⁻¹

EXAMPLE 14 Pivaloyloxymethyl3-acetylthio-7-oxo-4-thia-1-azabicyclo[3,2,0]hept-2-ene-2-carboxylate##STR40##

To a solution of 22 mg of pivaloyloxymethyl3-acetylthio-8-oxo-4,5-dithia-1-azabicyclo[4,2,0]oct-2-ene-2-carboxylatein deuterochloroform were added 14.7 mg of triphenylphosphine. TLCanalysis indicated complete conversion of the starting material and theproduct was shown by IR and NMR analysis to be the title compound. Thisproduct was isolated by chromatography on silica gel using ethylacetate/hexane mixtures as solvent. The yield of product was 13 mg(65%).

δ(CDCl₃) 1.22 (9H,S, --C(CH₃)₃), 2,47 (3H,S, ##STR41## 3.5(1H,2d,J_(trans) 2 Hz, 6-H), 3.9 (1H,2d, J_(cis) 4 Hz, J_(gem) 17 Hz,5.7 (1H,2d,5-H) 5.9 (2H,S,--CH₂ O--).

ν(CHCl₃) 1801, 1750, 1719 cm⁻¹

EXAMPLE 15 4-Nitrobenzyl3,3-di(acetylthio)-2-(4-allylthio-azetidin-2-on-1-yl)propenoate##STR42## EXAMPLE 15a

A solution of lithium hexamethyldisilazide was prepared by the additionof 5.12 ml of a 1.6M solution of n-butyllithium in hexane to 1.75 ml ofhexamethyldisilazane in 25 ml of dry THF at -10° with stirring, underargon. The solution was cooled to -78° and added by cannula to 1.57 g of4-nitrobenzyl 2-(4-allylthioazetidin-2-on-1-yl)acetate in 12 ml of dryTHF at -78°, with stirring under argon. After 5 minutes 0.846 ml ofcarbondisulphide was added by syringe. 1.77 ml of acetic anhydride werethen added, followed by 1.07 ml of glacial acetic acid. The solution wasallowed to warm to room temperature and evaporated to leave an orangeoil.

The crude product was chromatographed on silica gel usingdichloromethane/hexane mixtures as eluant. 0.541 g (23%) of pure productwas obtained.

δ(CDCl₃) 2.26 (3H,S, --C--CH₃), 2.38 (3H,S, ##STR43## 3.00-3.72(4H,m,3-H, S--CH₂ --) 5.01-6.44 (6H,m, HC═CH₂, --O--CH₂, 4-H) 7.33-8.34(4H,m, C₆ H₄)

ν_(max) (CDCl₃) 1785, 1742, 1716 cm⁻¹ ##STR44##

EXAMPLE 15b

A solution of lithium hexamethyldisilazide was prepared by the additionof 8.66 ml of a 1.6M solution of n-butyllithium in hexane to 2.96 ml ofhexamethyldisilazane in 30 ml of dry THF at -10° with stirring underargon. The solution was cooled to -78° and added by cannula to 2.07 g of4-nitrobenzyl 2-(4-allylthioazetidin-2-on-1-yl)acetate in 15 ml of dryTHF at -78°, with stirring, under argon. After 5 minutes 1.11 ml ofcarbon disulphide were added by syringe. 2.33 ml of acetic anhydridewere then added. The solution was allowed to warm to room temperatureand evaporated to give an orange oil. The oil was mixed with water (40ml) and chloroform (40 ml), the organic layer separated and the aqueouslayer extracted with additional chloroform (2×40 ml). The combinedorganic phase was dried (MgSO₄) and evaporated to give an orange oil,which was used without further purification as the starting material forExample 16b.

EXAMPLE 16 4-Nitrobenzyl3,3-di(acetylthio)-2-(4-allylsulphinylazetidin-2-on-1-yl)propenoate##STR45## EXAMPLE 16a

0.241 g of 3-chloroperbenzoic acid (81% pure) in 5 ml of ethyl acetatewas added dropwise over 20 minutes to a stirred solution of 0.534 g of4-nitrobenzyl3,3-di(acetylthio)-2-(4-allylthioazetidin-2-on-1-yl)propenoate in 10 mlof ethyl acetate at -35°. When TLC analysis indicated almost completeconversion of the starting material to product, the solution wasevaporated to dryness, slurried with dichloromethane and chromatographedon silica gel using ethyl acetate/hexane mixtures as eluant. 0.310 g(56%) of purified product was obtained.

δ(CDCl₃) 2.26 (3H,S, --C--CH₃), 2.42 (3H,S, --C--CH₃), 3.07-3.97(4H,m,3-H, S--CH₂), 5.23-6.39 (6H,m, HC═CH₂, --O--CH₂ --, 4-H), 5.38(2H,s, --O--CH₂ --), 7.57-8.37 (4H,m, --C₆ H₄)

ν_(max) (CDCl₃) 1795, 1732 cm⁻¹

EXAMPLE 16b

3.13 g of 3-chloroperbenzoic acid in 20 ml of ethyl acetate were addeddropwise over 20 minutes to a stirred solution in 10 ml of ethyl acetateof the 4-nitrobenzyl3,3-di(acetylthio)-2-(4-allythioazetidin-2-on-1-yl)propenoate obtainedin Example 15b at about -35°. TLC analysis indicated almost completeconversion of the starting material to product. The solution was thenevaporated to dryness, slurried with dichloromethane and chromatographedon silica gel using ethyl acetate/hexane mixtures as eluant 1.09 g ofpure product was obtained. (35% of the theoretical yield, calculated onthe starting material of Example 15b). For analytical data see Example16a.

EXAMPLE 17 4-Nitriobenzyl3-acetylthio-8-oxo-4,5-dithia-1-azabicyclo[4,2,0]oct-2-ene-2-carboxylate##STR46## EXAMPLE 17a

0.500 g of 4-nitrobenzyl3,3-di(acetylthio)-2-(4-allylsulphinyl-azetidin-2-on-1-yl)propenoate and0.192 g of toluenesulphonic acid hydrate were heated under reflux in 25ml of dioxan with stirring, under argon for 50 minutes, then TLCanalysis indicated completion of reaction. The crude product wasevaporated to dryness and chromatographed on silica gel using ethylacetate/hexane mixtures as eluant. 0.192 g (46%) of pure product wasobtained.

δ(CDCl₃) 2.37 (3H,S, ##STR47## 3.17 (1H,2d,J_(trans) 3 Hz, 7-H), 3.88(1H,2d,J_(cis) 5 Hz, J_(gem) 16 Hz, 7-H), 4.88 (1H,2d, 6-H), 5.38 (2H,S,--O--CH₂ --) 7.50-8.28 (4H,m, --C₆ H₄)

ν_(max) (CDCl₃) 1793, 1739 cm⁻¹

m/e 411.9933 (M⁺), 43.0209 (COCH₃) (base peak)

EXAMPLE 17b

The procedure described in Example 17a was carried out, refluxing 0.300g of the propenoate and 75.9 μl of boron trifluoride diethyl etheratefor 45 minutes. 0.102 g (41%) of purified product was obtained.

EXAMPLE 17c

The procedure described in Example 17a was carried out, using 0.200 g ofthe propenoate and 98 μl of boron trifluoride diethyl etherate and 50 μlof water in 5 ml of dioxan, and refluxing for 30 minutes. 0.087 g (54%)of purified product was obtained.

EXAMPLE 17d

The procedure described in Example 17a was carried out, refluxing 0.200g of the propenoate, 45 μl of stannic chloride, 50 μl of water and 5 mlof dioxan for 60 minutes. 0.052 g (32%) of purified product wasobtained.

EXAMPLE 18 4-Nitrobenzyl3-acetylthio-7-oxo-4-thia-1-azabicyclo[3,2,0]hept-2-ene-2-carboxylate##STR48##

0.186 g of 4-nitrobenzyl3-acetylthio-8-oxo-4,5-dithia-1-azabicyclo[4,2,0]oct-2-ene-carboxylatewas dissolved in 1.5 ml of deuterochloroform and 0.118 g oftriphenylphosphine was added. TLC and NMR analysis indicated completionof the reaction. The crude product was chromatographed on silica gel andeluted with ethyl acetate/hexane mixtures. 0.106 g (62%) of pure productwas obtained.

m.p. 145° (from ethyl acetate/hexane)

δ(CDCl₃) 2.45 (3H,S, ##STR49## 3.55 (1H,2d,J_(trans) 2 Hz, 6-H), 3.93(1H,2d,J_(cis) 4 Hz, J_(gem) 17 Hz, 6-H) 5.20 and 5.48 (2H, ABq, J 14Hz, --O--CH₂ --) 5.73 (1H, 2d, 5-H), 7.55-8.32 (4H,m, --C₆ H₄)

ν_(max) (CDCl₃) 1800, 1714 cm⁻¹

m/e 380.0196 (M⁺), 43.0210 (COCH₃) (base peak)

EXAMPLE 19 4-Nitrobenzyl7-oxo-3-thioxo-4-thia-1-azabicyclo[3,2,0]heptane-2-carboxylate ##STR50##

To a stirred solution of 100 mg of 4-nitrobenzyl3-acetylthio-7-oxo-4-thia-1-azabicyclo[3,2,0]hept-2-ene-2-carboxylate ina mixture of 2 ml of dioxan and 0.2 ml of water were added 19.6 mg ofimidazole. After 10 minutes the reaction mixture was diluted with 5 mlof 1M aqueous acid solution and extracted with dichloromethane (2×5 ml).The organic extracts were combined and backwashed with water (2×5 ml),then brine (5 ml), and finally dried and evaporated. The residue waschromatographed on silica gel, with elution by means of ethylacetate/hexane mixtures. Fractions containing the purified product werecombined and evaporated to leave an orange oil (43 mg, 48%).

δ(CDCl₃) 3.5 (1H,2d,J_(trans) 2 Hz, J_(gem) 16 Hz, 6-H), 4.14(1H,2d,J_(cis) 4 Hz, 6-H), 5.4 (2H,S, --CH₂ --), 5.5 (1H,S, --CH), 5.98(1H,2d, 5-H), 7.5-8.5 (4H,m, --C₆ H₄).

ν(CDCl₃) 1800, 1754 cm⁻¹

m/e 338.0003 (M⁺), 262(M--CS₂), 234(M--CS₂ --CO), ##STR51## 76(CS₂),54(base peak)

EXAMPLE 20 Methyl7-oxo-3-thioxo-4-thia-1-azabicyclo[3,2,0]heptane-2-carboxylate ##STR52##

To a stirred solution of 120 mg of methyl3-acetylthio-7-oxo-4-thia-1-azabicyclo[3,2,0]hept-2-ene-2-carboxylate ina mixture of 2 ml of dioxan and 0.2 ml of water were added 32 mg ofimidazole. After 15 minutes the reaction mixture was diluted with 5 mlof a 1M aqueous citric acid solution and extracted with ethyl acetate(2×5 ml). The ethyl acetate extracts were evaporated to dryness, theresidue slurried with chloroform and washed with water (2×5 ml). Thechloroform layers were dried and evaporated to leave a yellow oil (83mg, 83%).

δ(CDCl₃) 3.4 (1H,2d,J_(trans) 2 Hz, J_(gem) 16 Hz, 6-H), 3.8 (3H,S,--CH₃), 3.9 (1H,2d,J_(cis) 4 Hz, 6-H), 5.3 (1H,S), 2-H), 5.84 (1H,2d,5-H).

ν(CDCl₃) 1798, 1750 cm⁻¹

m/e 216.9875 (M⁺), ##STR53## 113 (CH₂ CHNCHCOOCH₃), 76 (CS₂), 54 (basepeak).

EXAMPLE 21 4-Allylthio-3-ethylazetidinone

To a solution of 1.06 g of sodium hydroxide in 14 ml of water were added2.82 ml of allylthiol. The solution was stirred under an argonatmosphere for 10 minutes. To this solution was added, over a period of1 minute, a solution of 3.79 g of ethyl acetoxyazetidinone in 6 ml ofwater. After about 15 minutes, when the starting material had beenconsumed, the solution was extracted three times with dichloromethane.The combined organic extracts were back-extracted with water, then driedover magnesium sulphate, evaporated in vacuo, and chromatographed oversilica gel, eluting with ethyl acetate/hexane mixtures. The main product(2.84 g) was trans 4-allylthio-3-ethylazetidinone, which contained atrace amount of the cis isomer. (Yield 2.84 g)

ν_(max) (CDCl₃) 1766 cm⁻¹

δ(CDCl₃) 1.04 (3H, t, J7 Hz), 1.75 (2H, q, J7 Hz), 2.96-3.18 (1H, m,3-H), 3.31 (2H, d, J7 Hz), 4.46 (1H, d, J_(trans) 2 Hz, 4-H), 5.04-6.46(3H, m), 6.81 (1H, s)

EXAMPLE 22 Methyl (4-allylthio-3-ethylazetidin-2-on-1-yl)acetate

To a solution of 2.34 g of 4-allylthio-3-ethylazetidinone in 20 ml ofredistilled dimethylformamide were added 1.37 ml of methyl bromoacetateand 4.16 g of ground potassium carbonate. The solution was stirredovernight then filtered through a pad of Hyflo, (Hyflo being a TradeMark), poured into 75 ml of water, and extracted five times with ethylacetate. The combined organic extracts were washed with water, driedover magnesium sulphate, and evaporated in vacuo to give the titlecompound. (Yield 3 g)

ν_(max) (CDCl₃) 1763, 1748 cm⁻¹

δ(CDCl₃) 1.07 (3H, t, J7 Hz), 1.77 (2H, q, 7 Hz), 3.04-3.36 (3H, m,3-H), 3.24 (2H, d, J6 Hz), 3.67 and 4.31 (2H, ABq, J18 Hz), 4.64 (1H, d,J_(trans) 2 Hz, 4-H), 4.94-5.40 (2H, m), 5.55-6.30 (1H, m)

EXAMPLE 23 (4-Allylthio-3-ethylazetidin-2-on-1-yl)acetic acid

To a solution of 3 g ofMethyl-(4-allylthio-3-ethylazetidin-2-on-1-yl)acetate in 10 ml ofabsolute ethanol was added, at room temperature and dropwise over 5minutes, a solution of 0.90 g of potassium hydroxide in a mixture of 12ml of ethanol and 1 ml of water. The resulting solution was then pouredinto 10 ml of dichloromethane, 13 ml of 2M hydrochloric acid and 20 mlof water were added, and the organic phase was separated. The aqueousphase was extracted twice with dichloromethane, and then the combineddichlormethane extracts were re-extracted with aqueous sodiumbicarbonate (2.7 mol equivalents in 27 ml) and then discarded. Theaqueous bicarbonate layer was then layered with dichloromethane andacidified to pH 1.5 with hydrochloric acid. The aqueous layer was thenfurther extracted with dichloromethane. The combined organic layer wasdried over magnesium sulphate and evaporated in vacuo to give the titlecompound as a colorless crystalline solid. (Yield 2.56 g)

δ(CDCl₃) 1.05 (3H, t, J7 Hz), 1.75 (2H, q, 7 Hz), 2.95-3.33 (3H, m,3-H), 3.19 (2H, d, J6 Hz), 3.65 and 4.29 (2H, ABq, J18 Hz), 4.56 (1H, d,J2 Hz, 4-H), 4.90-5.33 (2H, m), 5.45-6.19 (2H, m), 10.41 (1H, s).

EXAMPLE 24 4-Nitrobenzyl-(4-allylthio-3-ethylazetidin-2-on-1-yl) acetate

To a solution of 2.5 g of (4-allylthio-3-ethylazetidin-2-on-1-yl)aceticacid in 8 ml of dimethylacetamide was added 0.636 g of freshly groundsodium carbonate. After stirring for 20 minutes, 2.591 g of4-nitrobenzyl bromide were added in one batch. After about 45 minutes,when the starting material had been consumed, the solution was pouredinto water and extracted three times with ethyl acetate. The combinedorganic extracts were washed with saturated sodium bicarbonate, waterand saturated brine, and then dried over magnesium sulphate, evaporatedin vacuo and chromatographed on silica gel, eluting with ethylacetate/hexane mixtures to give the title compound as a pale yellow oil.(Yield 3.08 g)

ν_(max) (CDCl₃) 1750 cm⁻¹

δ(CDCl₃) 1.05 (3H, t, J7 HZ), 1.78 (2H, q, J7 Hz), 3.06-3.44 (3H, m,3-H), 3.22 (2H, d, J7 Hz), 3.77 and 4.38 (2H, ABq, J19 Hz), 4.63 (1H, d,J2 Hz, 4-H), 4.93-6.30 (5H,m), 5.20 (2H, s), 7.41-8.50 (4H, m).

EXAMPLE 254-Nitrobenzyl-2-(4-allylthio-3-ethylazetidin-2-on-1-yl)-3,3-bis(acetylthio)propenoate

To a well stirred solution of 12 g of 4-nitrobenzyl4-allylthio-3-ethylazetidin-2-on-1-yl)acetate in 75 ml of drytetrahydrofuran, which was cooled to -78° C. and held under an argonatmosphere, was added a solution of performed lithiumhexamethyldisilazane (prepared by adding 45.6 ml of butyllithium to asolution of 15.6 ml of hexamethyl-disilazane in 75 ml of tetrahydrofurancooled to -20° C. and then cooled to -78° C.). After stirring for 10minutes, 3.96 ml of carbon disulphide were added in one batch, andstirring was continued for a further 5 minutes. 12.48 ml of aceticanhydride were then added, and the solution was allowed to warm to roomtemperature. The solution was then extracted using ethyl acetate andwater. The aqueous phase was extracted again with ethyl acetate. Thecombined organic extracts were evaporated in vacuo and chromatographedover silica gel, eluting with ethyl acetate/hexane mixtures to give thetitle compound as a yellow oil. (Yield 12.19 g)

δ(CDCl₃) 1.06 (3H, t, J8 Hz), 1.75 (2H, q, J8 Hz), 2.28 (3H, s), 2.39(3H, s), 3.12-3.54 (3H, m), 3.35 (2H, d, J7 Hz, 3-H), 5.06 (1H, d,J_(trans) 3 Hz, 4-H), 6.09-6.35 (5H, m), 5.41 (2H, s), 7.54-8.45 (4H,m).

EXAMPLE 264-Nitrobenzyl-2-(4-allylsulphinyl-3-ethylazetidin-2-on-1-yl)-3,3-bis(acetylthio)propenoate

To a solution, cooled to -45° C., of 0.94 g of 4-nitrobenzyl2-(4-allylthio-3-ethylazetidin-2-on-1-yl)-3,3-bis-(acetylthio)propenoatein 10 ml of ethyl acetate was added portionwise a solution of 0.386 g ofm-chloroperbenzoic acid in 10 ml of ethyl acetate. When the reaction wascomplete, the solution was diluted with etthyl acetate, and then washedwith potassium metabisulphite, with saturated sodium bicarbonate, withwater, and finally with saturated brine. The resulting solution wasdried over magnesium sulphate and evaporated in vacuo to give the titlecompound. (Yield 0.96 g).

δ(CDCl₃) 0.84-1.30 (3H, m), 2.25 (3H, s), 2.39 (3H, s), 3.23-3.70 (3H,m), 3.24-3.71 (2H, m), 3.47 (2H, d, J6 Hz), 4.97 (1H, d, J_(trans) 3 Hz,4-H), 5.15-6.21 (5H, m), 5.35 (2H, s), 7.39-8.40 (4H, m)

EXAMPLE 27 4-Nitrobenzyl7-ethyl-8-oxo-3-acetylthio-4,5-dithia-1-azabicyclo[4,2,0]oct-2-ene-2-carboxylate

To a solution of 0.96 g of 4-nitrobenzyl2-(4-allyl-sulphinyl-3-ethylazetidin-2-on-1-yl)-3,3-bis(acetylthio)-propenoatein 25 ml of dioxan were added 0.52 ml of ethanol and 0.44 ml of borontrifluoride diethyletherate.

The solution, which was held under a positive pressure of argon, wasplaced in an oil bath preheated to 130° C., and allowed to reflux. Whenthe sulphoxide had been consumed, the solution was cooled quickly, andwas then diluted with ethyl acetate, washed with water and then withsaturated brine, and was then dried, and evaporated in vacuo to yieldthe title compound in crude form as an orange-yellow gum. (Yield 0.90g).

δ(CDCl₃) 0.86-1.34 (3H, m), 1.75-2.22 (2H, m), 2.36 (3H, s), 3.13-3.76(1H, m. 7-H), 4.65 (1H, d, J_(trans) 3 Hz, 6-H), 5.40 (2H, s), 7.49-8.44(4H, m)

EXAMPLE 28 4-Nitrobenzyl6-ethyl-7-oxo-3-acetylthio-4-thia-1-azabicyclo[3,2,0]hept-2-ene-2-carboxylate

To a solution of 0.90 g of 4-nitrobenzyl7-ethyl-8-oxo-3-acetylthio-4,5-dithia-1-azabicyclo[4,2,0]oct-2-ene2-carboxylate in 2 ml of dichloromethane was added, in one bath, asolution of 0.59 g of triphenylphosphine in 3 ml of dichloromethane.After 10 minutes, the reaction mixture was chromatographed directly onsilica gel, eluting with ethyl acetate/hexane mixtures, to give thetitle compound as a yellow crystalline solid. (Yield 0.25 g)

δ(CDCl₃) 1.02 (3H, t, J7 Hz), 1.93 (2H, q, J7 Hz), 2.40 (3H, s),3.45-4.14 (1H, m, 6-H), 5.07 and 5.39 (2H, ABq, J14 Hz), 5.65 (1H, d,J_(cis) 4 Hz, 5-H), 7.27-8.16 (4H, m).

EXAMPLE 29 4-Nitrobenzyl6-ethyl-7-oxo-3-thioxo-4-thia-1-azabicyclo[3,2,0]heptane 2-carboxylate

To a stirred solution of 0.25 g of 4-nitrobenzyl6-ethyl-7-oxo-3-acetylthio-4-thia-1-azabicyclo[3,2,0]hept-2-ene2-carboxylate in 4 ml of dioxan and 0.5 ml of water was added, in onebatch, 0.046 g of imidazole. After 10 minutes, the solution was dilutedwith 10 ml of 1M citric acid and extracted twice with dichloromethane.The combined organic extracts were washed with water, dried overmagnesium sulphate, and evaporated in vacuo to give the title compoundin a quantitative yield.

δ(CDCl₃) 1.04 (3H, t, J7 Hz), 1.81 (2H, q, J7 Hz), 3.53-4.08 (1H, m,6-H), 5.22-5.39 (3H, m, 2-H), 5.28 (2H, s), 5.99 (1H, d, J_(cis) 5 Hz,5-H), 7.35-8.33 (4H, m).

EXAMPLE 30

4(R)-Allylthio-3(S)-[1(R)-{dimethyl-{2-methylprop-2-yl}-silyloxy}ethyl]azetidin-2-one

To a stirred solution of 1.14 ml of allyl mercaptan and 0.4 g of sodiumhydroxide in 25 ml of water under an argon atmosphere was added asolution of 2.87 g of4-acetoxy-3(S)-[1(R)-{dimethyl-{2-methylprop-2-yl}silyloxy}ethyl]azetidin-2-onein 10 ml of methanol. After 30 minutes, the mixture was partitionedbetween dichloromethane and water. The separated organic layer waswashed with water, was dried over magnesium sulphate, evaporated todryness, and then chromatographed on silica gel. Elution with ethylacetate/hexane mixtures afforded 1.8 g of the title compound as whitecrystals.

ν.sub.(max) CDCl₃ 3420, 1767 cm⁻¹

δ(CDCl₃) 0.05 (6H, s), 0.88 (9H, s), 1.20 (3H, d, J6 Hz), 2.9-3.2 (3H,m), 3.9-4.3 (1H, m, H-1'), 4.84 (1H, d J₃,4 2 Hz, H-4), 4.95-6.3 (3H,m), 7.28 (1H, broad s)

EXAMPLE 31a Methyl2-(4-(R)-allylthio-3(S)-[1(R)-{dimethyl-{2-methylprop-2-yl}silyloxy}ethyl]azetidin-2-on-1-yl)acetate

To a stirred solution of 1.76 g of4(R)-allylthio-3(S)-[1(R)-{dimethyl-{2-methylprop-2-yl}silyloxy}ethyl]azetidin-2-one in 60 ml of dry dimethylformamide were added 3.52 g offinely ground potassium carbonate and 0.6 ml of methyl bromoacetate.After 18 hours, the mixture was filtered and then partitioned betweenethyl acetate and water. The separated organic layer was washed withwater and dried over magnesium sulphate. Evaporation in vacuo afforded acrude product which was chromatographed on silica gel. Elution withethyl acetate/hexane mixtures afforded 1.56 g of the title compound as apale yellow oil.

ν_(max) CDCl₃ 1753, 1768 cm⁻¹

δ(CDCl₃) 0.06 (6H, s), 0.86 (9H, s), 1.23 (3H, d J6.5 Hz), 3.2 (3H, m),3.70 (3H, s), 3.6-4.3 (3H, m), 4.87 (1H, d J 2 Hz, H-4), 4.9-6.3 (3H,m).

EXAMPLE 31b Methyl2-(4(S)-allylthio-3(S)-[1(R)-{dimethyl{2-methylprop-2-yl}silyloxy}ethyl]azetidin-2-on-1-yl)acetate

This compound was prepared analogously to its 4(R) isomer, as describedin Example 31a, using the corresponding 4(S) starting material.

EXAMPLE 32a 4-Nitrobenzyl2-(4(R)-allylthio-3(S)-[1(R)-{dimethyl-{2-methylprop-2-yl}silyloxy}ethyl]azetidin-2-on-1-yl)acetate

To a stirred solution of 3.04 g of potassium hydroxide in 80 ml of 95%ethanol was added a solution of 16 g of methyl2-(4(R)-allylthio-3(S)-[1(R)-{dimethyl-{2-methylprop-2-yl}silyloxy}ethyl]azetidin-2-on-1-yl)acetate.After 10 minutes, the mixture was evaporated to about 1/5 of itsoriginal volume; 2 ml of dimethyl acetamide were added, followed by asolution of 9.25 g of 4-nitrobenzyl bromide in 50 ml ofdimethylacetamide. After 1 hour, the mixture was partitioned between0.01M HCl and ethyl acetate. The separated organic layers were washedwith 0.01M HCl, with water, with cold, saturated sodium bicarbonate, andwith brine, and were then dried and evaporated. The resulting crudeproduct was chromatographed over silica gel; elution with ethylacetate/hexane mixtures afforded 19.5 g of the title compound as an oil.

ν_(max) (CDCl₃) 1755, 1769 cm⁻¹

δ(CDCl₃) 0.07 and 0.09 (6H, two singlets), 0.88 (9H, s), 1.25 (3H, d J6Hz), 3.2 (3H, m), 3.7-4.5 (3H, m), 4.95 (1H, d J2 Hz, H-4), 4.9-6.3 (5H,m), 7.5-8.35 (4H, m)

EXAMPLE 32b4-Nitrobenzyl-2-(4(S)-allylthio-3(S)-[1(R)-{dimethyl{2-methylprop-2-yl}silyloxy}ethyl]azetidin-2-on-1-yl)acetate

This compound was prepared analogously to its 4(R) isomer, as describedin Example 32a, using the corresponding 4(S) starting material.

EXAMPLE 33a 4-Nitrobenzyl3,3-bis(acetylthio)-2-(3(S)-allylthio[1(R)-{dimethyl-{2-methylprop-2-yl}silyloxy}ethyl]azetidin-2-on-1-yl)propenoate

A solution of lithium hexamethyldisilazide was prepared by the additionof n-butyllithium in hexane (2.79 ml of a 1.6M solution) to 0.982 ml ofhexamethyldisilazane in 8 ml of dry tetrahydrofuran at -10° C., whilestirring under argon. The solution was cooled to -78° C. and added bycannula to a solution of 0.98 g of 4-nitrobenzyl2-(4(R)-allylthio-3(S)-[1(R)-{dimethyl-{2-methylprop-2-yl}silyloxy}ethyl]azetidin-2-on-1-yl)acetatein 8 ml of dry tetrahydrofuran at -78° C., with stirring under argon.After 5 minutes, 0.357 ml of carbon disulphide was added by syringe,followed by 0.748 ml of acetic anhydride. The mixture was allowed towarm to room temperature, and 30 ml of dichloromethane were added,followed by 30 ml of water. The organic layer was separated, and theaqueous layer was extracted with further dichloromethane. The combinedorganic extracts were washed with 1M HCl, with water, and with a 12%sodium chloride solution, and were then dried over magnesium sulphateand evaporated to give 1.38 g of an orange oil. 1.21 g of this crudeproduct was chromatographed on silica gel using ethyl acetate/hexanemixtures as eluant to give 0.800 g of the title compound in purifiedform.

δ(CDCl₃) 0.10 (6H, s), 0.88 (9H, s), 1.35 (3H, d, J7 Hz), 2.24 (3H, s),2.37 (3H, s), 3.15-3.64 (3H, m, 3-H), 3.30 (2H, d, J7 Hz), 4.00-4.46(1H, m), 4.91-6.21 (6H, m), 5.30 (2H, s), 7.40-8.36 (4H, m).

EXAMPLE 33b 4-Nitrobenzyl 3,3-di(acetylthio)-2-((3S,4R)-4-allylthio-3-[1(R)-{dimethyl-{2-methylprop-2-yl}silyloxy}ethyl]azetidin-2-on-1-yl)propenoate

The above compound was prepared analogously to its 4(S) isomer, asdescribed in Example 33a, using the corresponding 4(R) startingmaterial.

ν_(max) (CDCl₃) 1778, 1745 cm⁻¹

δ(CDCl₃) 0.06 (6H, s), 0.85 (9H, s), 1.26 (3H, d, J6 Hz), 2.25 (3H, s),2.35 (3H, s), 3.11-3.52 (3H, m, 3-H), 3.35 (2H, d, J6 Hz), 4.14-4.39(1H, m), 4.95-6.30 (6H, m), 5.35 (2H, s), 5.56 (1H, d, J3 Hz, 4-H),7.44-8.38 (4H, m).

EXAMPLE 34a 4-Nitrobenzyl3,3-di(acetylthio)-2-((3S,4S)4-allylsulphinyl-3-[1(R)-{dimethyl-{2-methylprop-2-yl}silyloxy}ethyl]azetidin-2-on-1-yl)propenoate

0.080 g of 3-chloroperbenzoic acid in 2 ml of ethyl acetate was addeddropwise over 3 minutes to a stirred solution of 0.200 g of4-nitrobenzyl3,3-di(acetylthio)-2-((3S,4S)4-allylthio-3-[1(R)-{dimethyl-{2-methylprop-2-yl}silyloxy}ethyl]azetidin-2-on-1-ylproopenoate in 3 ml of ethyl acetate at 35° C. The organic solution waswashed with a potassium metabisulphite solution (0.5 g in 5 ml), withsaturated sodium bicarbonate solution and then with 12% brine. Theresulting organic solution was then dried over magnesium sulphate andevaporated to give a pale yellow foam. 0.205 g of the title compound wasobtained.

δ(CDCl₃) 0.12 (6H, s), 0.90 (9H, s), 1.20-1.60 (3H, m), 2.26 (3H, s),2.40 (3H, s), 3.39-4.01 (3H, m, 3-H), 3.57 (2H, d, J6 Hz), 4.37-4.85(1H, m), 5.15 and 5.19 (1H, 2d, J₄β,3β 6 Hz, 4-H), 5.22-6.28 (5H, m),5.36 (2H, s), 7.45-8.45 (4H, m).

EXAMPLE 34b 4-Nitrobenzyl3,3-di(acetylthio)-2-((3S,4R)4-allylsulphinyl-3-[1(R)-{dimethyl-{2-methylprop-2-}silyloxy}ethyl]azetidin-2-on-1-yl)propenoate

The above compound was prepared analogously to its 4(S) isomer, asdescribed in Example 34a, using the corresponding 4(R) startingmaterial.

EXAMPLE 35a 4-Nitrobenzyl 6(S),3-acetylthio-7(S)-[1(R)-hydroxyethyl]-8-oxo-4,5-dithia-1-azabicyclo[4,2,0]oct-2-en-2-carboxylate

To a solution of 0.205 g of 4-nitrobenzyl3,3-di(acetylthio)-2-((3S,4S)-4-allylsulphinyl-3-[1(R)-{dimethyl{2-methylprop-2-yl}silyloxy}ethyl]-2-azetidin-2-on-1-yl)propenoatein 5 ml of dioxan were added 27 μl of water followed by 61 μl of borontrifluoride diethyletherate. The mixture was then heated rapidly toreflux with stirring and under an argon atmosphere for 40 minutes. 5 mlof water were added to the reaction mixture, which was then extractedwith ethyl acetate. The organic phase was washed with water, dried overmagnesium sulphate, evaporated, and chromatographed on silica gel usingethyl acetate/hexane mixtures as eluant. 0.047 g of the title compoundwas obtained.

ν_(max) (CDCl₃) 1783, 1739 cm⁻¹

δ(CDCl₃) 1.45 (3H, d, J6 Hz), 2.23 (1H, s), 2.38 (3H, s), 3.97 (1H, 2d,J6 Hz, J10 Hz, 7-H), 4.22-4.65 (1H, m), 5.20-(1H, d, 6-H), 5.41 (2H, s),7.46-8.46 (4H, m)

EXAMPLE 35b 4-Nitrobenzyl 6(R),3-acetylthio-7(S)-[1(R)-hydroxyethyl]-8-oxo-4,5-dithia-1-azabicyclo[4,2,0]oct-2-en-2-carboxylate

This compound was prepared analogously to its 6(S) isomer, as describedin Example 35a, using the corresponding 4(R) starting material(described in Example 34b).

EXAMPLE 36a 4-Nitrobenzyl 3-acetylthio-6(S)-[1(R)-hydroxyethyl]-7-oxo-4-thia-1-azabicyclo[3,2,0]hept-2-ene-2-carboxylate

0.121 g of 4-nitrobenzyl 6(S),3-acetylthio-7(S)[1(R)-hydroxyethyl]-8-oxo-4,5-dithia-1-azabicyclo[4,2,0]oct-2-en-2-carboxylatewas dissolved in 3 ml of deuterochloroform and 0.070 g oftriphenylphosphine was added, with stirring at room temperature. After 5minutes, the crude product was chromatographed on silica gel usingdichloromethane/hexane and ethyl acetate/dichloromethane mixtures aseluant. 0.039 g of a mixture of the 5R and 5S isomers of the titlecompound was obtained.

δ(CDCl₃) 1.37 and 1.48 (3H, 2d, J7 Hz), 2.00 (1H, s), 2.46 (3H, s),3.52-4.12 (1H, m, 6-H), 4.12-4.57 (1H, m), 5.07-5.69 (2H, m), 5.75 and5.81 (1H, 2d, J₅α,6β 2 Hz J₅β,6β 5 Hz, 5-H), 7.54-8.46 (4H, m, --C₆ H₄)

EXAMPLE 36b 4-Nitrobenzyl3-acetylthio-6(S)-[1(R)-hydroxyethyl]-7-oxo-4-thia-1-azabicyclo[3,2,0]hept-2-ene-2-carboxylate

This compound was prepared analogously as described in Example 36a usingthe corresponding 6(R) starting material (described in Example 35b). Amixture of the 5(R) and 5(S) isomers was obtained.

EXAMPLE 37 4-Nitrobenzyl6(S)-[1(R)-hydroxyethyl]-7-oxo-3-thio-4-thia-1-azabicyclo[3,2,0]heptane-2-carboxylate

To a stirred solution of 0.039 g of 4-nitrobenzyl3-acetylthio-6(S)-(1(R)-hydroxyethyl)-7-oxo-4-thia-1-azabicyclo[3,2,0]hept-2-en-2-carboxylatein a mixture of 1.5 ml of dioxan and 0.15 ml of water was added 0.0069 gof imidazole at room temperature. After 5 minutes the mixture wasdiluted with 3 ml of 1M hydrochloric acid and 5 ml of water, and thenextracted into ethyl acetate. The combined organic extracts were washedwith water and dried over magnesium sulphate. The resulting solution wasevaporated to give a mixture of the 5R and 5S isomers of the titlecompound as a foam.

ν_(max) (CDCl₃) 1790, 1753 cm⁻¹

δ(CDCl₃) 1.10-1.61 (3H, m), 2.28 (1H, s), 3.57-4.05 (1H, m, 6-H),4.14-4.52 (1H, m), 5.35 (2H, s), 5.41 (1H, s, 2-H), 5.89 and 6.06 (1H,2d, J₅α,6β 1 Hz, J₅β,6β 4 Hz, 5-H), 7.35-8.40 (4H, m, --C₆ H₄)

EXAMPLE 38 4-Nitrobenzyl6-ethyl-3-ethylthio-7-oxo-4-thia-1-azabicyclo[3,2,0]hept-2-ene2-carboxylate

To a solution of 0.5 g of 4-nitrobenzyl6-ethyl-7-oxo-3-thioxo-4-thia-1-azabicyclo[3,2,0]heptane 2-carboxylatein 2 ml of dioxane was added, in one batch, 0.57 ml ofN-ethyldiisopropylamine, then 0.10 ml of bromoethane. When the reactionwas complete, the solution was evaporated in vacuo and chromatographedon silica gel, eluting with ethyl acetate/hexane mixtures to give thetitle product. (Yield 0.300 g)

ν_(max) (CDCl₃) 1789 cm⁻¹

δ(CDCl₃) 0.85-1.49 (6H, m), 1.77-2.26 (4H, m), 3.58-4.12 (1H, m, 6-H),5.16 and 5.50 (2H, AB_(q), J14 Hz), 5.41 and 5.77 (1H, 2d, J_(trans) 2Hz, J_(cis) 5 Hz, 5-H) 7.41-8.31 (4H, m).

EXAMPLE 39 4-Nitrobenzyl3-ethylthio-6(S)-[1(R)hydroxyethyl]-7-oxo-4-thia-1-azabicyclo[3,2,0]hept-2-en-2-carboxylate

To 0.200 ml of ethyl diisopropylamine was added to 0.426 g of4-nitrobenzyl6(S)-[1(R)-hydroxyethyl]-7-oxo-3-thioxo-4-thia-1-azabicyclo[3,2,0]heptane-2-carboxylatein dry tetrahydrofuran with stirring. 0.252 ml of iodoethane was thenadded and stirring was continued for 16 hours at room temperature. Thereaction mixture was then evaporated to dryness and chromatographed onsilica gel, eluting with ethyl acetate/hexane mixtures, to give thetitle product as a mixture of 5R and 5S isomers.

δ(CDCl₃) 1.38 (3H, d J6 Hz), 1.39 (3H, t), 2.02 (1H, s), 2.97 (2H, q),3.64-3.81 (1H, m, 6-H), 3.85-4.52 (1H, m), 5.15 and 5.48 (2H, AB_(q)),5.64 (1H, d J1 Hz, 5-H), 7.48-8.33 (4H, ABq).

EXAMPLE 40 4-Nitrobenzyl3-ethylthio-7-oxo-4-thia-1-azabicyclo[3,2,0]hept-2-ene 2-carboxylate

To a solution of 0.5 g of 4-Nitrobenzyl7-oxo-3-thio-4-thia-1-azabicyclo[3,2,0]heptane 2-carboxylate in 2 ml ofdioxane and 0.25 ml of water was added, in one batch, 0.57 ml ofN-ethyldiisopropylamine and then 0.11 ml of bromoethane. When thereaction was complete the solution was evaporated in vacuo andchromatographed on silica gel, eluting with ethyl acetate/hexanemixtures, to give 0.19 g of the title compound

ν_(max) (CDCl₃) 1791 cm⁻¹

δ(CDCl₃) 1.25 (3H, t, J7 Hz), 3.45 (1H, 2d, J_(trans) 2 Hz), 3.86 (1H,2d, J_(cis) 4 Hz, J_(gem) 16 Hz), 4.08 (2H, q, J7 Hz), 5.13 and 5.43(2H, d, J14 Hz), 5.66 (1H, 2d), 7.37-8.22 (4H, m).

We claim:
 1. A compound of the formula ##STR54## wherein R is a carboxylesterifying group removable by hydrolysis, photolysis, reduction, orenzyme action to give the free acid, andR₂ is hydrogen, lower alkyl,lower hydroxyalkyl, lower alkoxyalkyl, lower alkanoyloxyalkyl, ortri-lower alkylsilyloxyalkyl.
 2. A compound as in claim 1 wherein R₂ ismethyl, ethyl, hydroxymethyl, 2-hydroxyethyl, or 2-hydroxyprop-2-yl. 3.A compound as in claim 1 wherein R is p-nitrobenzyl, phthalidyl,pivaloyloxymethyl, acetylmethyl, or acetoxymethyl.
 4. A method as inclaim 1 wherein R₆, R₇, and R₈ are each phenyl.
 5. An antibacterialpharmaceutical preparation comprising an antibacterially effectiveamount of a compound as in claim 1 and a pharmaceutically acceptablecarrier therefor.
 6. A method for treating a bacterial infection in ahost suffering therefrom, which method comprises administering to saidhost an antibacterially effective amount of a compound as in claim
 1. 7.A method for making a compound as in claim 1 which comprises reacting acyclic compound of the formula ##STR55## with a tervalent phosphoruscompound of the formula

    PR.sub.6 R.sub.7 R.sub.8

wherein R₆, R₇, and R₈ are the same or different and are phenyl, loweralkyl, lower alkoxy, or di-loweralkyl amino, at a temperature from 0° to80° C. in a dry, inert, aprotic organic solvent or diluent.
 8. A methodas in claim 7 wherein at least one equivalent of tervalent phosphoruscompound is reacted per equivalent of said cyclic compound.